IDEAYA Biosciences

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before underwriting...

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the U.S. Food and Drug Administration (FDA) has...

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Novartis will present a poster with data from...

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the appointments of Frank McCormick, Ph.D., FRS, and William...

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the company is scheduled to present at the...

IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery and development of breakthrough precision medicines, announced today the appointment of Bao Truong, as vice president, head of regulatory...

IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, announced today the appointment of Paul Stone, J.D., as senior vice...